Cargando…

Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice

BACKGROUND: Amyloid plaques and neurofibrillary tangles (NFTs) are the defining pathological hallmarks of Alzheimer’s disease (AD). Increasing the quantity of the O-linked N-acetylglucosamine (O-GlcNAc) post-translational modification of nuclear and cytoplasmic proteins slows neurodegeneration and b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuzwa, Scott A, Shan, Xiaoyang, Jones, Bryan A, Zhao, Gang, Woodward, Melissa L, Li, Xiaojing, Zhu, Yanping, McEachern, Ernest J, Silverman, Michael A, Watson, Neil V, Gong, Cheng-Xin, Vocadlo, David J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232697/ https://www.ncbi.nlm.nih.gov/pubmed/25344697 http://dx.doi.org/10.1186/1750-1326-9-42

Ejemplares similares

Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation
por: Yu, Yang, et al.
Publicado: (2012)

Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb Glucohomeostasis
por: Macauley, Matthew S., et al.
Publicado: (2010)

Structural and functional insight into human O-GlcNAcase
por: Roth, Christian, et al.
Publicado: (2017)

Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb Glucohomeostasis
por: Macauley, M.S., et al.
Publicado: (2010)

Analysis of transition state mimicry by tight binding aminothiazoline inhibitors provides insight into catalysis by human O-GlcNAcase
por: Cekic, N., et al.
Publicado: (2016)

Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice
por: Hastings, Nicholas B., et al.
Publicado: (2017)

O-GlcNAcase contributes to cognitive function in Drosophila
por: Muha, Villo, et al.
Publicado: (2020)

Synergy of Peptide and Sugar in O-GlcNAcase Substrate Recognition
por: Schimpl, Marianne, et al.
Publicado: (2012)

O-GlcNAcase Expression is Sensitive to Changes in O-GlcNAc Homeostasis
por: Zhang, Zhen, et al.
Publicado: (2014)

Disruption of O-GlcNAc cycling by deletion of O-GlcNAcase (Oga/Mgea5) changed gene expression pattern in mouse embryonic fibroblast (MEF) cells
por: Keembiyehetty, Chithra
Publicado: (2015)

O-GlcNAcase: Promiscuous Hexosaminidase or Key Regulator of O-GlcNAc Signaling?
por: Alonso, Jana, et al.
Publicado: (2014)

Developmental Regulation of Protein O-GlcNAcylation, O-GlcNAc Transferase, and O-GlcNAcase in Mammalian Brain
por: Liu, Ying, et al.
Publicado: (2012)

Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds
por: Dorfmueller, Helge C., et al.
Publicado: (2010)

Structural studies of a surface-entropy reduction mutant of O-GlcNAcase
por: Males, Alexandra, et al.
Publicado: (2019)

Structural insights into the substrate binding adaptability and specificity of human O-GlcNAcase
por: Li, Baobin, et al.
Publicado: (2017)

Loss of O-GlcNAcase catalytic activity leads to defects in mouse embryogenesis
por: Muha, Villő, et al.
Publicado: (2021)

A fluorescent probe to simultaneously detect both O-GlcNAcase and phosphatase
por: Boo, Jihyeon, et al.
Publicado: (2023)

GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation
por: Dorfmueller, Helge C., et al.
Publicado: (2009)

O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies
por: Permanne, Bruno, et al.
Publicado: (2022)

Cell-Penetrant, Nanomolar O-GlcNAcase Inhibitors Selective against Lysosomal Hexosaminidases
por: Dorfmueller, Helge C., et al.
Publicado: (2010)

Design and Optimization of Thioglycosyl–naphthalimides as Efficient Inhibitors Against Human O-GlcNAcase
por: Shen, Shengqiang, et al.
Publicado: (2019)

O-GlcNAcase targets pyruvate kinase M2 to regulate tumor growth
por: Singh, Jay Prakash, et al.
Publicado: (2019)

Drosophila O-GlcNAcase Mutants Reveal an Expanded Glycoproteome and Novel Growth and Longevity Phenotypes
por: Akan, Ilhan, et al.
Publicado: (2021)

Pharmacological Inhibition of O-GlcNAcase Does Not Increase Sensitivity of Glucocorticoid Receptor-Mediated Transrepression
por: Stivers, Peter J., et al.
Publicado: (2015)

Target protein deglycosylation in living cells by a nanobody-fused split O-GlcNAcase
por: Ge, Yun, et al.
Publicado: (2021)

Short O-GlcNAcase Is Targeted to the Mitochondria and Regulates Mitochondrial Reactive Oxygen Species Level
por: Pagesy, Patrick, et al.
Publicado: (2022)

Mutation Hotspot for Changing the Substrate Specificity of β-N-Acetylhexosaminidase: A Library of GlcNAcases
por: Nekvasilová, Pavlína, et al.
Publicado: (2022)

Inhibition of O-GlcNAcase Using a Potent and Cell-Permeable Inhibitor Does Not Induce Insulin Resistance in 3T3-L1 Adipocytes
por: Macauley, M.S., et al.
Publicado: (2010)

Inhibition of O-GlcNAcase Using a Potent and Cell-Permeable Inhibitor Does Not Induce Insulin Resistance in 3T3-L1 Adipocytes
por: Macauley, Matthew S., et al.
Publicado: (2010)

PET quantification of brain O-GlcNAcase with [(18)F]LSN3316612 in healthy human volunteers
por: Lee, Jae-Hoon, et al.
Publicado: (2020)

Human O-GlcNAcase Uses a Preactivated Boat-skew Substrate Conformation for Catalysis. Evidence from X-ray Crystallography and QM/MM Metadynamics
por: Calvelo, Martín, et al.
Publicado: (2023)

Structure of a bacterial putative acetyltransferase defines the fold of the human O-GlcNAcase C-terminal domain
por: Rao, Francesco V., et al.
Publicado: (2013)

Region- and voxel-based quantification in human brain of [(18)F]LSN3316612, a radioligand for O-GlcNAcase
por: Lee, Jae-Hoon, et al.
Publicado: (2021)

An efficient and versatile synthesis of GlcNAcstatins—potent and selective O-GlcNAcase inhibitors built on the tetrahydroimidazo[1,2-a]pyridine scaffold
por: Borodkin, Vladimir S., et al.
Publicado: (2010)

Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathies
por: Hering, Heike, et al.
Publicado: (2013)

Bacterial O-GlcNAcase genes abundance decreases in ulcerative colitis patients and its administration ameliorates colitis in mice
por: He, Xiaolong, et al.
Publicado: (2021)

Defining the structural origin of the substrate sequence independence of O-GlcNAcase using a combination of molecular docking and dynamics simulation
por: Martin, Joanne C, et al.
Publicado: (2014)

A crystal structure-guided rational design switching non-carbohydrate inhibitors' specificity between two β-GlcNAcase homologs
por: Liu, Tian, et al.
Publicado: (2014)

Three-dimensional structure of a Streptomyces sviceus GNAT acetyltransferase with similarity to the C-terminal domain of the human GH84 O-GlcNAcase
por: He, Yuan, et al.
Publicado: (2013)

Involvement of NDPK-B in Glucose Metabolism-Mediated Endothelial Damage via Activation of the Hexosamine Biosynthesis Pathway and Suppression of O-GlcNAcase Activity
por: Chatterjee, Anupriya, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ird1pqonedcctchdb37j81nhkk